Description
XGEVA 120 MG is a powerful biological medication containing Denosumab, a human monoclonal antibody used to prevent serious bone complications in patients with advanced cancer. Manufactured by Amgen, it works as a RANK ligand (RANKL) inhibitor, effectively blocking the protein that signals the body to break down bone tissue. Xgeva is essential for preventing “skeletal-related events” (SREs) such as bone fractures, the need for radiation or surgery to the bone, and spinal cord compression in patients with bone metastases from solid tumors (such as breast, prostate, or lung cancer). It is also the primary treatment for Giant Cell Tumor of Bone that cannot be removed by surgery.
